FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration

NCT07004075 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Low-grade Glioma
Pediatric Low-grade Gliomas
pLGG With BRAF Alteration

Interventions

DRUG: Luvometinib
BIOLOGICAL: Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide

Sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.